Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

Leveraging the immunosuppressive function of SARS-CoV-2-encoding NSP2 to improve VSVd51 oncolytic efficacy

EF 2023-24

Résumé
A major drawback of traditional cancer treatments is that they not only target cancer cells but also damage healthy cells in the process. Oncolytic viral therapy is a promising form of cancer treatment that selectively targets and kills cancer cells. Oncolytic viruses are weakened viruses that exploit the fact that cancer cells, unlike healthy cells, have a defective antivirus defense system. These modified viruses can infect and kill cancer cells, while healthy cells remain unharmed. However, there are cancer types with fully functioning antivirus defenses that make them resistant to oncolytic viral therapy. My PhD project focuses on using SARS-CoV-2 to improve oncolytic viral therapy. SARS-CoV-2 makes a protein called NSP2, which has been shown to compromise a cell's ability to combat a viral infection. Importantly, this function of NSP2 relies on host protein 4EHP, which is found at higher levels in cancerous versus healthy tissue. Thus, since it requires 4EHP to limit the antiviral system, introducing NSP2 into a virus would improve its ability to kill specifically cancer cells, where 4EHP is found in higher amounts, while normal cells are still left unaffected. To test the hypothesis, I have engineered new oncolytic viruses that produce either NSP2 or a mutated version of NSP2 that does not interact with 4EHP. I will now use these new viruses to study how the interaction between 4EHP and NSP2 affects the ability of the latter to compromise cellular antiviral defenses. In addition, I will use these viruses to infect a series of cancer and healthy cell models, as well as tumour-bearing mice models, and compare their anti-cancer effects. Our findings will provide insight in the importance of 4EHP and NSP2 interacting in the context of combatting antiviral defenses to improve oncolytic viral therapy. By developing a better oncolytic virus, we can strengthen the field of oncolytic viral therapy and improve clinical outcomes of cancer patients.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
497120
Name
Ladak Reese
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Leveraging the immunosuppressive function of SARS-CoV-2-encoding NSP2 to improve VSVd51 oncolytic efficacy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
4ehp; Immunotherapy; Interferon-Beta; Nsp2; Oncolytic Viruses; Riboseq; Translation Repression; Tumour Mouse Models; Vsvd51
Abstract
A major drawback of traditional cancer treatments is that they not only target cancer cells but also damage healthy cells in the process. Oncolytic viral therapy is a promising form of cancer treatment that selectively targets and kills cancer cells. Oncolytic viruses are weakened viruses that exploit the fact that cancer cells, unlike healthy cells, have a defective antivirus defense system. These modified viruses can infect and kill cancer cells, while healthy cells remain unharmed. However, there are cancer types with fully functioning antivirus defenses that make them resistant to oncolytic viral therapy. My PhD project focuses on using SARS-CoV-2 to improve oncolytic viral therapy. SARS-CoV-2 makes a protein called NSP2, which has been shown to compromise a cell's ability to combat a viral infection. Importantly, this function of NSP2 relies on host protein 4EHP, which is found at higher levels in cancerous versus healthy tissue. Thus, since it requires 4EHP to limit the antiviral system, introducing NSP2 into a virus would improve its ability to kill specifically cancer cells, where 4EHP is found in higher amounts, while normal cells are still left unaffected. To test the hypothesis, I have engineered new oncolytic viruses that produce either NSP2 or a mutated version of NSP2 that does not interact with 4EHP. I will now use these new viruses to study how the interaction between 4EHP and NSP2 affects the ability of the latter to compromise cellular antiviral defenses. In addition, I will use these viruses to infect a series of cancer and healthy cell models, as well as tumour-bearing mice models, and compare their anti-cancer effects. Our findings will provide insight in the importance of 4EHP and NSP2 interacting in the context of combatting antiviral defenses to improve oncolytic viral therapy. By developing a better oncolytic virus, we can strengthen the field of oncolytic viral therapy and improve clinical outcomes of cancer patients.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ladak, Reese
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~